Clinical Trial Update: Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating the efficacy, safety, and tolerability of LDV/SOF treatment for HIV/HCV co-infected participants who switch to TAF-based regimen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Hepatitis C

Drugs mentioned

• Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide
• Emtricitabine/Rilpivirine/Tenofovir Alafenamide (emtricitabine/rilpivirine/tenofovir alafenamide)
• Ledipasvir/sofosbuvir (Ledipasvir and sofosbuvir)

Snippet

Sponsor: Gilead Sciences | Conditions: HIV-1 Infection, HCV Infection | Phase 3 | Status: COMPLETED | Results posted: 2018-10-09